Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot-and-mouth disease virus

Journal of Gene Medicine

Volumn 7, Issue 6, 2005, Pages 708-717

  Yang, Ning Sun ^a,b   Wang, Jeng Hwan ^a   Lin, Ku Feng ^a   Wang, Chien Yu ^a   Kim, Suk Am ^a   Yang, Yu Ling ^a   Jong, Ming Hwa ^c   Kuo, Tsun Yung ^b   Lai, Shiow Suey ^b   Cheng, R Holland ^d   Chan, Ming Tsair ^a   Liang, Shu Mei ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FISHERIES RESEARCH INSTITUTE   (Taiwan)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Capsid protein; DNA vaccine; FMDV; Immunogenicity; Viral clearance

Indexed keywords

CAPSID PROTEIN; COMPLEMENTARY DNA; DNA VACCINE; NEUTRALIZING ANTIBODY; POLYPEPTIDE P1; PROTEIN VP1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; DNA SEQUENCE; DNA VECTOR; ELECTROPORATION; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE EXPRESSION; GENE GUN; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; VACCINATION;

FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE;

EID: 21044450075     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.723     Document Type: Article

References (41)

1. Yang PC, Chu RM, Chung WB, Sung HT. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet Rec 1999; 145: 731-734.
2. Stone R. Report Urges U.K. to vaccinate herds. Science 2002; 297: 319-321.
3. Rueckert RR. Picornaviridae: the viruses and their replication. In Virology, Fields BN, Knipe DM, Howley PH (eds). Lippincott-Raven Publishers: Philadelphia, PA, 1996; 609-654.
4. Acharya R, Fry E, Stuart D, et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature 1989; 337: 709-716.
5. Doel TR, Chong WKT. Comparative immunogenicity of 146S, 75S, and 12S particles of foot-and-mouth disease virus. Arch Virol 1982; 73: 185-191.
6. Grubman MJ, Morgan DO, Kendall J, et al. Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol 1985; 56: 120-126.
7. Rowlands DJ, Sangar DV, Brown F. A comparative chemical and serological study of the full and empty particles of foot-and-mouth disease virus. J Gen Virol 1975; 26: 227-238.
8. Rweyemamu MM, Terry G, Pay TWF. Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol 1979; 59: 69-79.
9. Petit MC, Benkirane N, Guichard G, et al. Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site. Structural basis for its antigenic cross-reactivity with the parent peptide. J Biol Chem 1999; 274: 3686-3692.
10. Brown F, Benkirane N, Limal D, et al. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif. Vaccine 1999; 18: 50-56.
11. Harrison SC. Picornaviruses. Finding the receptors. Nature 1989; 388: 205-206.
12. Mateu MG, Martinez MA, Capucci L, et al. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol 1990; 71: 629-637.
13. Liu MA, Ulmer JB. Gene-based vaccines. Mol Ther 2000; 1: 497-500.
14. Oshikawa K, Rakhmilevich AL, Shi F, et al. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther 2001; 12: 149-160.
15. Collen T, Baron J, Childerstone A, et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen. Virus Res 1998; 56: 125-133.
16. Mulcahy G, Pullen LA, Gale C, et al. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines. Vaccine 1991; 9: 19-24.
17. Barteling SJ, Woortmeyer R. Multiple variants in foot-and-mouse disease virus (FMDV) populations: the Achilles heel for peptide and rec. DNA vaccines? Dev Biol Stand 1987; 66: 511-521.
18. Domingo E, Verdaguer N, Ochoa WF, et al. Biochemical and structural studies with neutralizing antibodies raised against foot-and-mouth disease virus. Virus Res 1999; 62: 169-175.
19. Weidt G, Deppert W, Utermohlen O, et al. Emergence of virus escape mutants after immunization with epitope vaccine. J Virol 1995; 69: 7147-7151.
20. Taboga O, Tami C, Carrillo E, et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 1997; 71: 2606-2614.
21. Ward G, Rieder E, Mason PW. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol 1997; 71: 7442-7447.
22. Chinsangaram J, Beard C, Mason PW, et al. Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol 1998; 72: 4454-4457.
23. Beard C, Ward G, Rieder E, et al. Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J Biotechnol 1999; 73: 243-249.
24. Benvenisit L, Rogel A, Kuznetzova L, et al. Gene gun-mediated DNA vaccination against foot-and-mouth disease virus. Vaccine 2001; 19: 3885-3895.
25. Cedillo-Barron L, Foster-Cuevas M, Belsham GJ, et al. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol 2001; 82: 1713-1724.
26. Huang H, Yang Z, Xu Q, et al. Recombinant fusion protein and DNA vaccines against foot and mouth disease virus infection in guinea pig and swine. Viral Immunol 1999; 12: 1-8.
27. Wong HT, Cheng SCS, Chan EWC, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 2000; 278: 27-35.
28. Robbins AK, Watson RJ, Whealy ME, et al. Characterization of a pseudorabies virus glycoprotein gene with homology to herpes simplex virus type 1 and type 2 glycoprotein C. J Virol 1986; 58: 339-347.
29. Wang J-H, Liang CM, Peng JM, et al. Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus. Vaccine 2003; 21: 3721-3729.
30. Kuo C-F, Wang J-H, Yang N-S. Direct gene transfer and vaccination via skin transfection using a gene gun, In Methods in Molecular Medicine, vol. 69, Gene Therapy Protocols, (2nd edn), Morgan JR (ed). Humana Press Inc.: Totowa, NJ, 2002; 137-147.
31. Kadowaki S, Chen Z, Asanuma H, et al. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine 2000; 18: 2779-2788.
32. Wang CY, Chang TY, Walfield AM, et al. Synthetic peptide-based vaccine and diagnostic system for effective control of FMD. Biologicals 2001; 29: 221-228.
33. Mahvi D, Burkholder JK, Tuner J, et al. Particle-mediated gene transfer of GM-CSF cDNA to tumor cells: implications for a clincally relevant tumor vaccine. Hum Gene Ther 1996; 7: 1535-1543.
34. Qiu P, Ziegelhoffer P, Sun J, et al. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther 1996; 3: 262-268.
35. Mayr GA, O'Donnell V, Chinsangaram J, et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2001; 19: 2152-2162.
36. Dunn CS, Samuel AR, Pullen LA, et al. The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. Virology 1998; 247: 51-61.
37. Wigdorovitz A, Carrillo C, Dus Santos MJ, et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999; 255: 347-353.
38. pro) structure: basis for design of anti-SARS drugs Science 2003; 300: 1763-1767.
39. Xing L, Tjarnlund K, Lindquist B, et al. Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J 2000; 19: 1207-1216.
40. Bittle JL, Houghten RA, Alexander H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982; 298: 30-33.
41. Kitson JD, McCahon D, Belsham GJ. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology 1990; 179: 26-34.